Lion Corp. engages in the manufacture and sale of dental and body care, laundry, household cleaners, pharmaceuticals, and health products. It operates through the following business segments: Consumer Products, Industrial Products, Overseas, and Other. The Consumer Products segment manufactures and sells daily necessities, over-the-counter drugs and function food. These include toothpaste, toothbrush, hand soap, antipyretic analgesic, eye drops, nutritional drink, laundry detergent, softener, and bleach. The Industrial Products segment provides chemical raw materials and business supplies. These include oil and fat activator, conductive carbon, and professional cleaning agent. The Overseas segment handles the operation of overseas subsidiaries that manufactures and sells daily commodities. The Other segment includes construction contracting, real estate management, transportation storage, and staffing. The company was founded by Tomijiro Kobayashi on October 30, 1891 and is headquartered in Tokyo, Japan.

Mochida Pharmaceutical is a drug manufacturing company. Their pharmaceutical business aims to develop and market a broad spectrum of innovative new drugs. They also offer creates skin care products for the general public, and these are supplied through pharmacies, and drugstores.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Imperial Chemical Industries (ICI) was a British chemical company and was, for much of its history, the largest manufacturer in Britain. It was formed by the merger of leading British chemical companies in 1926. Its headquarters were at Millbank in London, and it was a constituent of the FT 30 and later the FTSE 100 indices.

R.P. Scherer GmbH & Co. KG, part of Catalent, Inc., is a company headquartered in Eberbach, Germany, that develops, manufactures and sells pharmaceutical products.

Beijing Shengyiyao Technology Development Co., Ltd., established on 2001-04-02, The business scope includes the sale of third-class medical devices;Production of Class III medical devices;technology development,consult,Serve,transfer;software development;selling computers,Software and Auxiliary Equipment,medical instrumentsIkind,medical instrumentsIIkind;Import and export;Technology Import and Export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Production of Class III medical devices,Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Kewpie Corp. engages in the manufacture and sale of food products. It operates through the following business segments: Condiment and Seasoning, Salad and Delicatessen, Egg, Fruit Solutions, Fine Chemicals, Distribution, and Common. The Condiment and Seasoning segment manufactures and sells mayonnaise, dressings, vinegar, pasta sauce, baby food, and nursing food products. The Salad and Delicatessen segment provides salads and side dishes. The Egg segment offers egg products such as liquid egg, frozen egg, soft boiled egg, omelets, egg salad, and processed egg. The Fruit Solutions segment supplies processed fruit products to dairy and food manufacturers such as jams, peanut cream, and terrine spread. The Fine Chemicals segment provides hyaluronic acid as an ingredient for pharmaceuticals, food, and cosmetics. The Distribution segment deals with food transportation and storage services. The Common segment includes the sale of food and manufacturing machinery. The company was founded by Toichiro Nakashima on November 30, 1919 and is headquartered in Tokyo, Japan.

Reckitt Benckiser Healthcare (UK) Ltd., a subsidiary of Reckitt Benckiser Group Plc, is a British company located in Slough. The firm manufactures household and sanitary goods. It was founded in 1931.\nThe company says this about itself: The principal activity of the company which is a Member of the Reckitt Benckiser group of companies is the manufacture and sale of branded consumer products for sale to other Group companies.

Qingdao Haizhilin Biotechnology Development Co., Ltd., established on 2010-12-09, Business scope includes production and sales of food additives,Compound food additives,food(issued by the Food and Drug Administration<National industrial production permit>Carry out business activities);Production,processing,Sales:Industrial Sodium Alginate,Industrial Alginic Acid,Industrial Calcium Alginate,Industrial Potassium Alginate,Industrial Alginate,Industrial Alginate Thickener;Sales of food additives,PGA(Propylene glycol alginate),Agar(The above range does not contain dangerous chemicals),cosmetic,steel,wood,rubber products,Hardware,Class II mechanical and electrical products,Office Supplies;Import and export,Technology Import and Export(law,Except for items prohibited by administrative regulations,law,Projects restricted by administrative regulations can only be operated after obtaining a license);Research and development of marine biological products,technical consulting;Foreign investment with self-owned funds;Own asset operation management(Not approved by financial regulators,Not to engage in deposit taking,financing guarantee,Financial services such as wealth management on behalf of clients)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Qingdao Bright Moon Seaweed Group Co., Ltd. is a private company headquartered in Qingdao, China, that manufactures seaweed and sugar alcohol products.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Shandong Jiejing Group Co. Ltd. is a Chinese private company located in Rizhao that gathers seaweed and manufactures kelp, and other marine products.

Société des Produits Nestlé SA engages in the manufacture and distribution of food, pharmaceutical, medical, and cosmetic products. The company was founded on December 15, 1936 and is headquartered in Vevey, France.

Hubei China Tobacco Industry Co. is a private company headquartered in Guangshui, China, that manufactures cigarettes.

Cresilon is a medical device company that produces and markets solutions for trauma care. The company’s proprietary product, VETIGEL, is a hemostatic gel made from plant-derived materials to stop traumatic bleeding in seconds. It functions as a blood-clotting agent, and also as a scaffold to facilitate skin growth. Cresilon was co-founded by Joe Landolina and Isaac Miller in 2010 and is based in New York, United States.

Chuzhou Cigarette Material Factory, established on 1996-05-17, Business scope includes[Production,manufacture]carton,filter stick,Flakes,Aluminum foil,paper jam,Cigarette tipping paper,Other cigarette material supporting services,finishing,repair;Warehousing Services(Removal of hazardous chemicals);equipment(Except special equipment)Maintenance and installation service(Involving qualifications and operating with qualifications);cigarette,food(Only branches can operate within the validity period of the license),Daily necessities,Labor protection supplies,Cultural office supplies,Hardware Accessories,Computer and Consumables Sales;Packaging and decoration printed matter,Other printed matter printing;road general freight;Car rental;Production and sales of electronic products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Wuhan Yellow Crane Tower Flavors & Fragrances Co., Ltd., established on 2006-10-30, Business scope includes technology development and product sales of cosmetics;agricultural products,cultivation of forest products,buy;Tobacco flavor,Spice Technology Project R&D,Transfer and Consulting Services;Tobacco flavor,spices,Additives and Flavors and Flavors,Food additives and other daily chemical products(Does not contain dangerous goods)technology development,Production,processing,Sales;Production of Sheet Materials for Tobacco,Sales;drinks(Chrysanthemum wolfberry drink),candy,Hard candy production and sales;Sales of recycled materials.(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.